Criteria for MET-driven lung cancer suitable for crizotinib treatment
Many cancers include increased copies of the gene MET. But in which cases is MET driving the cancer and in which do these increased copies happen to ‘ride along’ with other molecular abnormalities that are the true cause of the disease? The answer influences whether a tumour will respond to drugs that inhibit MET, like […]
